Targeted Antiestrogens to Prevent Breast Cancer

Area of Science:

• Pharmacology
• Oncology
• Endocrinology

Background:

• Selective estrogen receptor modulators (SERMs) represent a significant advancement in hormone therapy.
• Tamoxifen, the first SERM, has demonstrated efficacy in reducing breast cancer risk and enhancing bone density.
• Raloxifene is approved for osteoporosis prevention and shows preliminary breast cancer risk reduction.

Purpose of the Study:

• To evaluate the comparative efficacy of tamoxifen and raloxifene in breast cancer prevention.
• To assess the impact of these SERMs on bone density in women at risk for breast cancer.
• To gather further clinical evidence on the long-term benefits and risks of SERMs.

Main Methods:

• The Study of Tamoxifen and Raloxifene (STAR) is a large-scale, prospective clinical trial.
• Participants are women at increased risk for breast cancer.
• Randomized controlled trial design comparing tamoxifen and raloxifene.

Main Results:

• Preliminary data suggests both tamoxifen and raloxifene may reduce breast cancer incidence.
• Further analysis is ongoing to determine the full spectrum of benefits, including effects on bone health.
• The STAR trial is designed to provide robust evidence over a seven-year period.

Conclusions:

• SERMs like tamoxifen and raloxifene hold significant potential for breast cancer prevention.
• Ongoing research through the STAR trial will elucidate their comparative effectiveness and safety profiles.
• These findings are crucial for informing clinical practice and public health strategies regarding breast cancer risk reduction.